前瞻性研究:碘油分布作为传统经动脉化疗栓塞术治疗肝脏恶性肿瘤时多柔比星药代动力学的影像标志物
这项前瞻性临床试验纳入30例接受传统经动脉化疗栓塞术(cTACE)的肝脏恶性肿瘤患者,评估碘油分布与多柔比星(DOX)及多柔比星醇(DOXOL)药代动力学的关系。按碘油分布分为1个段、≥2个段和叶性cTACE三组,DOX峰浓度随分布范围增大而升高(p=0.036);基线强化肿瘤体积(ETV)和Child-Pugh B分级也是剂量归一化DOX峰浓度的预测因素;高ETV和肿瘤碘油覆盖与肿瘤反应相关。
要点
- 碘油分布范围(1段 vs ≥2段 vs 叶性)可预测cTACE后多柔比星峰浓度,叶性分布者DOX-Cmax最高。
- 基线强化肿瘤体积(ETV)高和Child-Pugh B分级是剂量归一化DOX峰浓度较高的额外预测因素。
- 基线ETV和肿瘤碘油覆盖可按qEASL标准预测cTACE后的体积肿瘤反应。
核心结论
- 这项前瞻性临床试验提供更新的药代动力学数据,揭示碘油分布可作为预测肝癌cTACE后DOX-Cmax和肿瘤反应的影像标志物。
研究设计与样本
- 前瞻性临床试验(ClinicalTrials.gov:NCT02753881),纳入30例连续接受cTACE的肝脏恶性肿瘤患者(2016年5月至2018年10月),使用50 mg DOX/10 mg丝裂霉素C与乙碘油按1:2乳化。
- 外周血于10个时间点采样,采用标准非房室分析计算峰浓度(Cmax)和剂量归一化(DN)曲线下面积(AUC)。
- 影像标志物包括cTACE后CT上的碘油分布(分为1个段 n=10、≥2个段 n=10、叶性cTACE n=10)和基线强化肿瘤体积(ETV)。
- cTACE后3-4周记录不良事件(AEs)和MRI上的肿瘤反应;统计方法包括重复测量ANOVA(RM-ANOVA)、Mann-Whitney检验、Kruskal-Wallis检验、Fisher精确检验和Pearson相关。
诊断标准与关键数值
- 按碘油分布分层,DOX-Cmax从1个段(DOX-Cmax 83.94 ± 75.09 ng/mL;DN-DOX-Cmax 2.67 ± 2.02 ng/mL/mg)升至≥2个段(DOX-Cmax 139.66 ± 117.73 ng/mL;DN-DOX-Cmax 3.68 ± 4.20 ng/mL/mg)再升至叶性分布(DOX-Cmax 334.35 ± 215.18 ng/mL;DN-DOX-Cmax 7.11 ± 4.24 ng/mL/mg;p = 0.036)。
- DN-DOX-AUC差异无统计学意义;RM-ANOVA显示1个段、≥2个段和叶性cTACE比较时DOX(p = 0.023)和DOXOL(p = 0.041)的时间浓度曲线显著分离。
- DN-DOX-Cmax较高的额外指标包括高ETV(p = 0.047)和Child-Pugh B分级(p = 0.009)。
- 高ETV和肿瘤碘油覆盖也与肿瘤反应相关;按定量欧洲肝病研究学会(qEASL)标准评估体积肿瘤反应。
临床应用与阅片要点
- cTACE后CT上的碘油分布范围(1个段 vs ≥2个段 vs 叶性)可作为预测DOX-Cmax的影像标志物。
- 基线ETV和肿瘤碘油覆盖可预测按qEASL标准评估的体积肿瘤反应。
- 分段cTACE后不良事件发生频率较低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the prognostic potential of Lipiodol distribution for the pharmacokinetic (PK) profiles of doxorubicin (DOX) and doxorubicinol (DOXOL) after conventional transarterial chemoembolization (cTACE).
METHODS: This prospective clinical trial ( ClinicalTrials.gov : NCT02753881) included 30 consecutive participants with liver malignancies treated with cTACE (5/2016-10/2018) using 50 mg DOX/10 mg mitomycin C emulsified 1:2 with ethiodized oil (Lipiodol). Peripheral blood was sampled at 10 timepoints for standard non-compartmental analysis of peak concentrations (Cmax) and area under the curve (AUC) with dose normalization (DN). Imaging markers included Lipiodol distribution on post-cTACE CT for patient stratification into 1 segment (n = 10), ≥ 2 segments (n = 10), and lobar cTACE (n = 10), and baseline enhancing tumor volume (ETV). Adverse events (AEs) and tumor response on MRI were recorded 3-4 weeks post-cTACE. Statistics included repeated measurement ANOVA (RM-ANOVA), Mann-Whitney, Kruskal-Wallis, Fisher's exact test, and Pearson correlation.
RESULTS: Hepatocellular (n = 26), cholangiocarcinoma (n = 1), and neuroendocrine metastases (n = 3) were included. Stratified according to Lipiodol distribution, DOX-Cmax increased from 1 segment (DOX-Cmax, 83.94 ± 75.09 ng/mL; DN-DOX-Cmax, 2.67 ± 2.02 ng/mL/mg) to ≥ 2 segments (DOX-Cmax, 139.66 ± 117.73 ng/mL; DN-DOX-Cmax, 3.68 ± 4.20 ng/mL/mg) to lobar distribution (DOX-Cmax, 334.35 ± 215.18 ng/mL; DN-DOX-Cmax, 7.11 ± 4.24 ng/mL/mg; p = 0.036). While differences in DN-DOX-AUC remained insignificant, RM-ANOVA revealed significant separation of time concentration curves for DOX (p = 0.023) and DOXOL (p = 0.041) comparing 1, ≥ 2 segments, and lobar cTACE. Additional indicators of higher DN-DOX-Cmax were high ETV (p = 0.047) and Child-Pugh B (p = 0.009). High ETV and tumoral Lipiodol coverage also correlated with tumor response. AE occurred less frequently after segmental cTACE.
CONCLUSIONS: This prospective clinical trial provides updated PK data revealing Lipiodol distribution as an imaging marker predictive of DOX-Cmax and tumor response after cTACE in liver cancer.
KEY POINTS: • Prospective pharmacokinetic analysis after conventional TACE revealed Lipiodol distribution (1 vs. ≥ 2 segments vs. lobar) as an imaging marker predictive of doxorubicin peak concentrations (Cmax). • Child-Pugh B class and tumor hypervascularization, measurable as enhancing tumor volume (ETV) at baseline, were identified as additional predictors for higher dose-normalized doxorubicin Cmax after conventional TACE. • ETV at baseline and tumoral Lipiodol coverage can serve as predictors of volumetric tumor response after conventional TACE according to quantitative European Association for the Study of the Liver (qEASL) criteria.
引用
- Savic LJ, Chapiro J, Funai E, et al. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. Eur Radiol. 2020. PMID: 33063185. doi:10.1007/s00330-020-07380-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。